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Mice are a preferred species for many avenues of 
immunological research in vivo. Because of the 
evolutionary divergence of mouse and man 65 
million years ago, however, these two species 
have inhabited different ecological niches and 
have been challenged with minimally overlapping 
groups of pathogens. The human and mouse im-
mune systems, evolving to meet these challenges, 
have therefore accumulated many differences (1), 
making genes related to immunity, together with 
genes involved in reproduction and olfaction, the 
most divergent between the two species (2).
Pathogens that drive this divergence are those 
that exclusively infect either humans or mice 
with a high frequency of population penetration 
and life-threatening pathology. One such exam-
ple is EBV, a human -herpesvirus that infects 
>90% of the human adult population. Humans 
are the only known natural reservoir for EBV, 
and this virus is associated with malignancies of 
lymphocyte and epithelial cell origin (3, 4). EBV 
is thought to cause or contribute to these life-
threatening tumors by its ability to induce prolif-
eration and to protect infected cells from apoptosis 
(5). All EBV-associated lymphomas and carcino-
mas express latent EBV antigens, whereas lytic 
EBV particle production does not cause signifi-
cant pathology. Latent EBV antigen expression 
differs between the various EBV-associated ma-
lignancies. Burkitt lymphoma expresses only the 
nuclear antigen 1 of EBV (EBNA1) as the sole 
latent gene product (latency I). In contrast, Hodg-
kin lymphoma and nasopharyngeal carcinoma 
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Many pathogens that cause human disease infect only humans. To identify the mechanisms 
of immune protection against these pathogens and also to evaluate promising vaccine 
candidates, a small animal model would be desirable. We demonstrate that primary T cell 
responses in mice with reconstituted human immune system components control infection 
with the oncogenic and persistent Epstein-Barr virus (EBV). These cytotoxic and interferon-
–producing T cell responses were human leukocyte antigen (HLA) restricted and specific 
for EBV-derived peptides. In HLA-A2 transgenic animals and similar to human EBV carriers, 
T cell responses against lytic EBV antigens dominated over recognition of latent EBV anti-
gens. T cell depletion resulted in elevated viral loads and emergence of EBV-associated 
lymphoproliferative disease. Both loss of CD4+ and CD8+ T cells abolished immune control. 
Therefore, this mouse model recapitulates features of symptomatic primary EBV infection 
and generates T cell–mediated immune control that resists oncogenic transformation.
© 2009 Strowig et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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human. However, although signs of primary immune responses 
were reported in all three of these current mouse models of   
human immune system reconstitution, the protective value of 
this immunocompetence and, thus, the potential of these in 
vivo systems as challenge models for vaccine development 
against pathogens with exclusive tropism for humans has not 
been evaluated. Therefore, we analyzed the ability of mice with 
reconstituted immune system components to exert antigen-
specific T cell–mediated control of EBV infection and EBV- 
associated lymphomas.
RESULTS
Immune reconstitution of NOD-scid c
/ mice injected 
with human CD34+ HPCs
To generate mice susceptible to EBV infection and, hence, 
potentially capable of generating EBV-specific human im-
mune responses in vivo, we compared previously described 
mouse models for human immune system reconstitution 
(NOD-scid c
/ and Rag2/ c
/ mice) (13–16). For this 
purpose we engrafted irradiated newborn Rag2/ c
/ and 
NOD-scid c
/ mice with human fetal liver–derived CD34+ 
HPCs. We observed higher levels of overall reconstitution 
and, in particular, human T and NK cell reconstitution in 
NOD-scid c
/ mice (unpublished data), and therefore pur-
sued this model, which we will refer to as hu-NSG mice in 
the remainder of the text.
We consistently achieved reconstitution of 20–50 hu-NSG 
mice from the same graft with similar B and T cell frequen-
cies in peripheral blood by 3 mo (Fig. S1 A). Frequencies of 
human CD45+ cells routinely exceeded 60% of total spleno-
cytes after 4 mo of reconstitution (Fig. S1 B), with the major-
ity (80–90%) being B and T cells (ratios of 2:1 for B to T cells, 
and 3:2 for CD4+ to CD8+ T cells). Additionally, CD123+ 
plasmacytoid cells (1–2%) and CD11c+ conventional dendritic 
cells (1–2%), monocytes (3–5%), and NK cells (2–5%) also 
engrafted (Fig. S1 B and not depicted). Furthermore, human 
CD45+ cells and all major subsets of human immune cells 
were detected in the thymus, mesenteric lymph node, bone 
marrow, liver, and lung of hu-NSG mice (unpublished data). 
Compared with the structured architecture in human second-
ary lymphoid organs like lymph nodes and tonsils, immune 
cells in the spleens of hu-NSG mice showed a primitive orga-
nization into white and red pulp (Fig. S1 C). In line with pre-
vious findings, we therefore successfully achieved human 
multilineage reconstitution in NOD-scid c
/ mice after neo-
natal HPC transfer, thus generating a small animal model with 
the potential to generate human immune responses in vivo.
EBV infection of humanized mice
To test the reconstituted human immune system’s ability to 
generate pathogen-specific immune control, we infected hu-
NSG mice with EBV, an oncogenic human virus that is effi-
ciently controlled by infected individuals with normal immune 
function. We chose an infectious dose that would approxi-
mate the number of virus particles in 100 µl of saliva from a 
symptomatic EBV converter (18). After injection of hu-NSG 
express, in addition, one or both latent membrane proteins 
(LMPs), LMP1 and 2 (latency II). Only in immune-compro-
mised patients, like HIV-infected individuals or transplant re-
cipients, do B cell lymphomas occur that express the five 
additional EBNA proteins 2, 3A, B, C, and LP (latency III). In 
addition, all EBV-infected B cells express small nontranslated 
virally encoded RNAs, including the EBV-encoded RNAs 
(EBERs). All three types of EBV latencies can also be found in 
healthy EBV carriers, and this graded EBV protein expression 
depends on the B cell differentiation stage of the infected cell   
(6, 7). Healthy virus carriers therefore have already established 
tumor-associated latent EBV protein expression. Hence, the in-
creased risk of immune-compromised individuals to develop 
EBV-associated tumors indicates loss of EBV-specific immune 
control that normally prevents viral tumorigenesis.
T cells constitute the decisive component of EBV-specific 
immune control against virus-associated malignancies because 
adoptive transfer of EBV-specific T cell lines can eradicate EBV-
associated posttransplant lymphomas (8). During primary infec-
tion, CD8+ T cells targeting epitopes of EBV lytic antigens 
make up the majority of EBV-specific T cells, but T cells target-
ing latent epitopes can also be detected. Different latency pat-
terns confer different degrees of immunogenicity for recognition 
by cytotoxic CD8+ and helper CD4+ T cells (9, 10). In healthy 
EBV carriers, the EBNA3 proteins are the dominant targets of 
CD8+ T cell responses, whereas EBNA1, 2, and 3C are the 
most consistently recognized CD4+ T cell antigens. In contrast, 
the LMPs are subdominant T cell antigens. At least a subset of 
investigated CD4+ and CD8+ T clones, however, recognize 
both dominant and subdominant specificities directly on EBV-
infected cells. Both CD4+ and CD8+ T cells therefore contrib-
ute to immune control against virus-infected cells (11), in 
addition to maintenance of functional CD8+ T cell memory by 
CD4+ T cells (12).
The lack of an animal model of EBV infection prevents as-
signment of a protective value to the known T cell reactivities. 
Design and evaluation of vaccines against EBV-associated   
tumors and symptomatic primary infection, however, require 
knowledge about the degree of protection conferred by differ-
ent EBV-specific immune responses. Mouse models that par-
tially reconstitute human immune system components after 
engraftment of hematopoietic progenitor cells (HPCs) are of 
particular interest to study vaccine candidates and EBV-specific 
immune responses in vivo. In this respect, three novel models 
of human immune system reconstitution are being considered. 
The first one uses BALB/c Rag2/ c
/ mice, which recon-
stitute macrophages, T cells, B cells, natural killer cells, and den-
dritic cells after neonatal intrahepatic HPC transfer (13, 14). 
The second model reconstitutes NOD-scid c
/ mice by intra-
venous injection of human HPCs (15, 16), which also leads to 
significant development of human myeloid and lymphoid cells. 
Finally, the most labor-intensive model is the BLT mouse, 
which requires implantation of human fetal liver and thymus 
pieces under the kidney capsule of NOD-scid mice in addition 
to intravenous HPC injection (17). Immune compartment re-
constitution in peripheral blood of BLT mice is very similar to JEM VOL. 206, June 8, 2009 
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EBV infection (Fig. 1 C). These results indicate that hu-NSG 
mice establish latent EBV infection, which constitutes the 
basis of B cell transformation by EBV.
Development of HLA-restricted EBV-specific human T cell 
responses in infected hu-NSG mice
Because we rarely observed tumors after 6 wk of infection in 
hu-NSG mice, we investigated whether they developed EBV-
specific T cell responses, such as those that protect healthy 
human carriers from EBV-associated malignancies (9, 10). For 
this purpose, we first analyzed the splenic lymphocyte compo-
sition of the infected animals by flow cytometry. We found 
dramatic expansions of CD3+ T cells among the human CD45+ 
leukocytes after EBV infection, which correlated with an in-
crease in the percentage of CD8+ cells among the human   
T cells (Fig. 2 A). On average, there was a statistically signifi-
cant twofold expansion of splenic CD3+ CD8+ T cells in 10 
independent experiments with a total of 40 mice (Fig. 2 B). In 
addition, in both the CD8+ and the CD4+ T cell compart-
ments, there was a marked-up regulation of HLA-DR and 
CD45RO surface expression, indicating an activated memory 
phenotype of the expanded T cells, similar to that seen in hu-
mans during symptomatic primary EBV infection (9, 10).
We next examined whether T cells from infected ani-
mals would respond to autologous EBV-transformed B cells 
presenting viral antigens by human MHC molecules. For this 
purpose, we first established lymphoblastoid cell lines (LCLs) 
by in vitro infection of B cells derived from a littermate mouse 
reconstituted with cells from the same HPC donor used for 
reconstitution of the EBV-infected animals. B cell–depleted 
splenocytes isolated from control and infected animals were 
incubated with these autologous LCLs, and IFN- secretion 
was monitored by ELISPOT assays. Autologous LCLs stimu-
lated significant amounts of IFN- production, whereas re-
sponses to allogeneic LCLs were comparable to background 
IFN- production (Fig. 3, A and B). Animals infected with 
higher doses of EBV also developed more vigorous EBV-spe-
cific T cell responses (Fig. 3 A), indicating that T cells can 
be primed in a dose-dependent manner in hu-NSG mice. 
Pretreatment of LCLs with antibodies against HLA-A/B/C, 
HLA-DR/DP/DQ, or both blocked their recognition (Fig. 3 B 
and not depicted). These data clearly demonstrate that HLA-
restricted, EBV-specific CD8+ and CD4+ human T cells were 
primed in hu-NSG mice upon infection with EBV.
Isolation of EBV-specific T cell clones
To analyze the peptide epitope specificity and effector functions 
of the in vivo–primed EBV-specific T cell responses, we iso-
lated splenocytes from hu-NSG mice reconstituted with HLA-
A2+ HPCs 10 wk after EBV infection. After labeling with 
CFSE, these splenocytes were stimulated with either autolo-
gous LCLs or a pool of 33 peptides derived from lytic and latent 
EBV antigens (Fig. 4 A). To enrich for LCL- or peptide-spe-
cific cells, CFSElow T cells were sorted after 6 d by flow cytom-
etry, cloned by limiting dilution, and finally retested with either 
autologous LCLs or the pool of 33 EBV-derived peptides in 
mice with 105 Raji-infecting units (RIU) of purified viral 
particles  intraperitoneally,  EBV-infected  cells  were  readily 
detectable in the spleen 4 wk after infection by in situ hybrid-
ization for EBERs. EBER+ cells were not detected in mock-
infected animals (Fig. 1 A). At later time points, we also 
detected EBER+ cells in the lymph nodes and livers of most 
infected animals (Fig. 1 A). In the spleens of infected animals, 
EBER+ cells were consistently surrounded by CD3+ T cells 
(Fig. 1 B). Furthermore, when EBER+ cells were detected in 
nonlymphoid organs such as liver and kidney, these infected 
cells were again in close proximity to CD3+ T cells, suggest-
ing that T cells can home to similar peripheral sites as EBV-
infected cells in hu-NSG mice (Fig. 1 B). To characterize the 
latency type of EBV-infected cells, we stained spleen sections 
for the two EBV-encoded proteins EBNA2 and LMP1. We 
did not detect any LMP1 single-positive cells, but we found 
similar frequencies of EBNA2+ compared with EBER+ cells, 
some of which also expressed LMP1, indicating latency III–type 
Figure 1.  EBV-infected cells are detected in hu-NSG mice in mul-
tiple organs and express EBNA2 and LMP1. (A) EBV-infected cells 
could be detected in the indicated organs by EBER hybridization.  
(B) EBER+ cells were surrounded by T cells (CD3+) both in the spleen and 
after migration to the kidney. (C) EBNA2+ cells coexpressed LMP1 in the 
spleen (the right panel is a magnification of the left panel). These analyses 
were performed 4–6 wk after EBV infection. Data are representative of 
three independent experiments. Bars, 100 µm.1426 PROTECTIVE IMMUNE RESPONSES AGAINST EBV IN MICE | Strowig et al.
infected hu-NSG mice, we aimed to bias EBV-specific T cell 
recognition to peptide epitopes that dominate EBV-specific 
immune control in humans by introducing a HLA-A2 trans-
gene into NSG mice. We reconstituted a group of regular NSG 
mice and NSG mice transgenic for HLA-A2 (NSG-A2) with 
CD34+ cells from the same HLA-A2+ donor. Human immune 
cells and, in particular, human CD4+ and CD8+ T cells devel-
oped in both groups of mice with similar frequencies and dis-
tributions (Fig. S2 A). Furthermore, transgenic expression of 
HLA-A2 did not influence homeostatic proliferation and sur-
vival of T cells (Fig. S2, B and C). We infected hu-NSG and 
hu-NSG-A2 mice with EBV, and 5 wk after infection we stim-
ulated splenocytes from these mice with two pools of EBV- 
derived HLA-A2–restricted peptides, one containing 8 lytic 
epitopes and one containing 12 latent epitopes (Table S1). We 
detected IFN- secretion by ELISPOT after stimulation with 
the lytic pool in all five EBV-infected hu-NSG-A2 mice, but 
only in four out of five mice after stimulation with the latent 
pool (Fig. 5 A). Notably, these latent responses were signifi-
cantly lower than the lytic responses (11 vs. 70 SFU/2 × 105 
cells; P = 0.04). Moreover, no IFN-–secreting cells were de-
tected in any of the control mice or in EBV-infected hu-NSG 
mice reconstituted with HLA-A2+ matching (n = 2) or non-
matching (n = 8) CD34+ cells against the used peptide pools   
ex vivo. Interestingly, after stimulation with autologous LCLs, 
IFN- ELISPOT assays. Three CD8+ T cell clones recognized 
the library of 33 peptides, and subsequent testing against a ma-
trix of smaller peptide libraries identified the individual peptides 
recognized by the clones (Fig. 4 A). All three clones recognized 
the LMP1167-176 peptide (Fig. 4 A), which is recognized by 
CD8+ T cells in EBV-infected HLA-A2+ individuals (10). Ti-
tration of the cognate peptide demonstrated high affinity recog-
nition by the clones (Fig. 4 B).
We also identified CD4+ and CD8+ T cell clones that rec-
ognized the autologous LCLs in IFN- ELISPOT assays. Sub-
sequently,  we  compared  the  cytotoxicity  of  three  of  these 
LCL-specific  clones  (#1–3)  and  one  of  the  LMP1-specific 
CD8+ T cell clones (CD8-LMP1) against autologous LCLs, 
and found that one of the two CD4+ T cell clones, the LCL-
specific CD8+ T cell clone, and the LMP1-specific CD8+  
T cell clone lysed autologous LCLs at similar effector/target 
ratios (Fig. 4 C). These T cells also degranulated and secreted 
IFN- upon LCL recognition (Fig. 4 D). These data indicate 
that multifunctional cytotoxic EBV-specific T cells are primed 
in hu-NSG mice and can kill EBV-transformed B cells.
Improved detection of dominant EBV peptide–specific CD8 
T cell responses in HLA-A2 transgenic hu-NSG mice
Because we were able to identify EBV-derived peptide epi-
topes for our isolated T cell clones only occasionally from EBV-
Figure 2.  Expansion of human CD3+ T cells after EBV infection. (A) Splenocytes from control or EBV-infected animals were harvested 6 wk after 
infection. Frequencies of lymphocyte subsets were determined by flow cytometry. Activation and memory phenotypes of both the CD4+ and CD8+ T cells 
were monitored by measuring the up-regulation of the HLA-DR and CD45RO surface markers, respectively. Representative data from 10 experiments are 
shown. (B) Summary of CD3+CD8+ T cell expansion for 40 mice in 10 different experiments. Horizontal bars represent means.JEM VOL. 206, June 8, 2009 
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cells in control hu-NSG and hu-NSG-A2 mice as well as in 
EBV-infected hu-NSG mice, in three out of five EBV-infected 
hu-NSG-A2 mice up to 2.7% of the CD8+ T cells stained posi-
tive with the BRLF1YVL tetramer (Fig. 5 C). These tetramer-
positive cells had an activated phenotype that was exclusively 
CD45RO+HLA-DR+ (unpublished data). But, in these mice 
we also did not observe any cells positive for the LMP2CLG tet-
ramer, possibly because their frequency was too low. These ex-
periments suggest that HLA transgenic hu-NSG mice bias 
primary T cell responses of reconstituted human immune sys-
tem components toward recognition of EBV-derived peptide 
epitopes that are dominant during EBV infection in humans.
Disseminated EBV-associated malignancies  
in T cell–depleted hu-NSG mice
To study the role of these in vivo–primed EBV-specific T cells 
to control EBV infection and EBV-associated malignancies 
in hu-NSG mice, we depleted T cells before EBV infection 
using antibodies against CD4 and CD8 (Fig. S3). 4–5 wk   
after infection, mice were analyzed for the development of 
tumors as well as for EBV viral loads. Although we observed 
small splenic tumors in only 3 out of the 17 EBV-infected 
animals with or without isotype control antibody injection, 
all 11 T cell–depleted animals developed disseminated EBV-
positive tumors in the spleen, mesenteric lymph node, kid-
ney, and/or liver (Fig. 6 A). Histological analysis showed 
expansion of white pulp regions in the enlarged spleens of   
T cell–depleted and EBV-infected mice, which contained   
almost exclusively EBER+ CD20+ B cells (Fig. 6 B and not 
depicted). Morphologically these proliferations destroyed the 
underlying architecture of the tissue. They consisted of a 
polymorphous cell population composed of atypical large 
transformed cells (some of which resembled Reed-Sternberg 
variants), plasmacytoid cells, small lymphocytes, and histio-
cytes. Areas of coagulative necrosis were often also present. 
Overall,  these  proliferations  resembled  the  EBV-associated 
polymorphic lesions seen in bone marrow and solid organ 
transplant recipients. The majority of these cells expressed 
EBNA2, once again indicating EBV latency III (Fig. 6 B). 
EBER+ cells located in the lymph node, liver, and kidney 
showed a similar phenotype (Fig. S4 and not depicted). In ad-
dition, lytic EBV replication, which was barely detectable 
during controlled primary EBV infection in vivo, as assessed 
by immunohistochemical staining for the immediate early 
EBV antigen BZLF1, was also increased in T cell–depleted 
hu-NSG mice 4 wk after EBV infection (Fig. S5). Further-
more, viral DNA loads increased significantly in T cell–de-
pleted mice (3.2 × 106 vs. 1.9 × 105 per 106 splenocytes [P = 
0.003] and 1.1 × 108 vs. 1.6 × 107 per spleen [P = 0.04]), in-
dicating uncontrolled EBV infection after T cell depletion 
(Fig. 7, A and B). Notably, viral loads did not significantly dif-
fer between EBV-infected hu-NSG and hu-NSG-A2 mice 
(Fig. S6). To compare the contributions of CD4+ and CD8+ 
T cells to the T cell–mediated immune control of EBV infec-
tion, we then depleted T cell subsets separately (Fig. 7, C and D). 
Viral titers increased significantly both after the depletion   
splenocytes from both EBV-infected hu-NSG and hu-NSG-A2 
mice responded similarly (107 vs. 124 SFU/2 × 105 cells). To 
detect EBV-specific CD8+ T cells directly, splenocytes were 
stained with control tetramers (HIV GAGSLY), and two well-
characterized  EBV  tetramers  derived  from  a  lytic  epitope 
(BRLF1YVL) and a latent epitope (LMP2CLG), respectively 
(Fig. 5 B). Although we did not detect any tetramer-positive 
Figure 3.  Dose-dependent induction of HLA-restricted T cell  
responses against autologous EBV-transformed B cells in infected 
hu-NSG mice. (A) Reconstituted NSG mice were infected with 105 or 106 
RIU EBV. 6 wk after infection, human B cell–depleted splenocytes were 
incubated with autologous EBV-transformed B cells (LCLs) to measure 
EBV-specific IFN- secretion using ELISPOT assays. IFN-–specific spots 
per 105 cells are shown for a representative experiment with three mice 
in each group. One representative out of six experiments is shown.  
(B) Humanized NSG mice were infected with 106 RIU EBV. 6 wk after infec-
tion, splenocytes were harvested from control and infected animals, and  
T cell reactivity was evaluated by IFN- ELISPOT assays under similar condi-
tions as described in A. Staphylococcal enterotoxin B (SEB) superantigen 
and allogenic LCLs were used as positive and negative controls, respec-
tively. Human HLA restriction was determined using inhibitory antibodies 
against HLA I and II as indicated. One representative out of two experi-
ments is shown. Data represent means + SD. SFC, spot-forming cells.1428 PROTECTIVE IMMUNE RESPONSES AGAINST EBV IN MICE | Strowig et al.
and CD8+ T cells contribute to the successful immune control 
of EBV in this model.
DISCUSSION
In this paper, we describe the first mouse model with protective 
immune control of the human persistent and oncogenic EBV. 
We demonstrate that primary T cell responses stabilize EBV load 
at high levels and prevent the development of EBV-associated 
malignancies. We propose that NOD-scid c
/ mice with re-
constituted human immune system components provide a chal-
lenge model for testing the efficacy of vaccines against this 
human oncogenic virus, and for the characterization of innate 
and adaptive immune responses during primary EBV infection.
Although no similarly oncogenic -herpesviruses of the 
EBV-containing genus Lymphocryptoviridae (lymphocryptoviruses)   
of CD4+ and CD8+ T cells compared with EBV-infected   
animals (EBV, 6.4 × 105; CD4, 1.9 × 106; CD8, 3.2 × 106; 
and CD4+CD8, 1.3 × 107 per 106 splenocytes [P < 0.03]; 
and EBV, 1.5 × 107; CD4, 7.2 × 107; CD8, 1.2 × 108; and 
CD4+CD8, 8.6 × 108 per spleen [P < 0.03]). However, 
neither the separate depletion of CD4 or CD8 T cells increased 
the viral titers as much as the depletion of both CD4+ and 
CD8+ T cells in these experiments. Notably, we observed the 
occurrence of tumors in the spleens and mesenteric lymph 
nodes in all four pan–T cell–depleted and in three out of four 
CD8-depleted animals, but only in one out of four CD4- 
depleted animals. These results therefore demonstrate that hu-
NSG mice are able to prime human EBV-specific T cell 
responses that protect mice against uncontrolled EBV infection 
and EBV-associated malignancies. Furthermore, both CD4+ 
Figure 4.  Isolation of EBV-specific T cell clones from infected hu-NSG mice. (A) T cell clones were established by limiting dilution cloning from sorted 
CFSElow T cells of spleens from animals 6 wk after EBV infection. These T cells had proliferated in response to EBV-transformed B cells (LCLs) or EBV-derived 
peptides. The library of 33 EBV peptides that was used for the initial T cell proliferation was divided into the indicated matrix of peptide pools and used to 
assess the fine specificity of obtained T cell clones. Reactivity of one out of three CD8+ T cell clones specific for the HLA-A2–restricted peptide LMP1167-176 in 
IFN- ELISPOT is shown. (B) Epitope affinity was determined by cognate peptide titration on LMP1167-176–specific CD8+ T cells in IFN- ELISPOT assays. One 
representative out of two experiments is shown. (C) The cytotoxicity of LMP1167-176–specific (CD8-LMP1) and LCL-specific (#1–3) CD4+ and CD8+ T cell clones 
against autologous EBV-transformed B cells (LCLs) was assessed by flow cytometric TO-PRO-3-iodide exclusion assays at the indicated effector/target ratios 
(E/T). One representative out of three experiments is shown. (D) Degranulation and IFN- production were evaluated after co-culture with autologous LCLs by 
flow cytometric surface staining for CD107a and intracellular IFN- staining (percentages are shown). One representative out of three experiments is shown.JEM VOL. 206, June 8, 2009 
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were  able  to  prime  MHC  class  II–restricted  CD4+CD8+  
T cells with cytotoxicity against EBV-transformed B cells (22). 
In rhesus macaques, strong cytotoxic and IFN-–secreting   
T cell responses against the monkey virus homologues of the 
EBNA1 antigen and the immediate early lytic EBV antigen 
BZLF1 were consistently detected in infected animals (20, 21). 
In BLT mice, EBV infection elicited low levels of IFN-–
  secreting, HLA-restricted T cell responses against autologous 
EBV-transformed B cells (17), and in reconstituted BALB/c 
Rag2/ c
/ mice, T cell proliferation against autologous 
EBV-transformed B cells was detected after EBV infection 
(13). None of these animal models, however, has investigated 
the protective value of EBV-specific primary T cell responses 
in  vivo,  and  the  level  of  IFN-–producing  EBV-specific   
T cell responses was also about 5- to 10-fold lower than in 
the present study. In addition, we report that EBV infection 
in hu-NSG mice elicited cytotoxic- and epitope-specific pri-
mary T cell responses with protective effector functions (9).
These primary immune responses control EBV infection 
at high levels of viral load, with massive expansion and acti-
vation of the CD8+ T cell compartment. These features are 
reminiscent of symptomatic primary EBV infection, called 
infectious mononucleosis (IM). Such a phenotype seems to 
be even more pronounced in hu-NSG mice, because they 
carry a 10-fold elevated viral load in their splenocytes, com-
pared with 104 viral DNA copies per 106 peripheral blood 
mononuclear cells in IM patients (18, 23). Of course, this 
assumes that the frequency of EBV-infected cells is similar 
in peripheral blood and spleen during IM, as has been shown 
for healthy virus carriers (24). Therefore, the reconstituted 
human immune system in hu-NSG mice has difficulty con-
trolling EBV infection, similar to chronic active EBV in-
fection in bone marrow transplantation recipients. Indeed, 
approximately 105 viral DNA copies per 106 peripheral blood 
mononuclear cells have been observed in >50% of chronic ac-
tive EBV patients, and these also occasionally develop tumors 
(25, 26). Nevertheless, the reconstituted human immune sys-
tem protects most infected mice from EBV-associated malig-
nancies. In contrast, T cell–depleted mice resemble, with their 
10-fold increase in EBV viral loads and the dissemination of 
EBV-induced B cell lymphomas to various tissues, EBV-associ-
ated lymphoproliferative disease in transplant recipients (8, 27). 
In addition, in both immunocompetent and T cell–depleted 
mice, we primarily detect coexpression of EBER, EBNA2, and 
LMP1 in EBV-infected cells. This indicates latency III–type 
cells, which also form the basis of EBV-associated lymphopro-
liferative disease in immune-compromised patients. Further-
more, these lesions morphologically resemble those seen in the 
organ transplant patient population (28). Therefore, EBV-in-
fected hu-NSG mice control EBV infection at high viral loads 
with hallmarks of IM and develop EBV-associated lymphopro-
liferative disease after T cell depletion.
Both CD8+ and CD4+ T cells contribute to the control of 
viral infection. In the case of EBV, in vitro studies have dem-
onstrated that CD8+ T cells mainly kill infected cells, whereas 
CD4+ T cells provide help for CD8+ T cells but can also 
has been identified in rodents to date (19), priming of immune 
responses to human (EBV) or closely related monkey lym-
phocryptoviruses has been observed after infection in rhesus 
macaques (20, 21), cottontop tamarins (22), and in the two 
other novel models of immunocompetent human immune 
system reconstitution in mice (13, 17). Cottontop tamarins 
Figure 5.  Enhanced priming of CD8+ T cell responses against dom-
inant EBV peptides in HLA-A2 transgenic hu-NSG mice. (A) HLA-A2 
transgenic and nontransgenic NSG mice were reconstituted with HLA-A2+ 
CD34+ HPCs from the same donor. 4 wk after EBV infection or mock treat-
ment, splenocytes were restimulated for IFN- ELISPOT assays with me-
dium alone, staphylococcal enterotoxin B (SEB) as a positive control, the 
autologous EBV-transformed B cell line (LCLs), 8 lytic EBV antigen–derived 
dominant CD8+ T cell epitopes, and 12 latent EBV antigen–derived CD8+  
T cell epitopes, which had been defined as dominant CD8+ T cell epitopes 
in human EBV carriers. The data summarize two independent experiments. 
(B and C) In parallel, tetramer staining on splenocytes of EBV-infected or 
control mice was performed ex vivo. Tetramers of HLA-A*0201 with the 
HIV gag aa 77–85 (GAGSLY), EBV LMP2 aa 426–434 (LMP2CLG), or EBV 
BRLF1 aa 109–117 (BRLF1YVL) peptides were used in costaining with anti-
CD8 and analyzed by flow cytometry (percentages are shown). B shows a 
representative experiment and C shows the summary of two independent 
experiments. Horizontal bars represent means.1430 PROTECTIVE IMMUNE RESPONSES AGAINST EBV IN MICE | Strowig et al.
trations of human IgG accumulating in the plasma of reconsti-
tuted mice over time, we were unable to detect EBV-specific 
IgG or IgM responses against the viral capsid antigen in EBV-
infected mice (unpublished data). We nevertheless cannot ex-
clude that humoral responses might develop against other EBV 
antigens and perhaps at later time points of infection, as we 
have observed for EBNA1 in an experimental vaccine study 
using  the  same  mouse  model  (29).  Indeed,  IgM  responses 
against the lytic EBV antigen BFRF3 were recently reported 
after 6 wk of EBV infection in a subset of NOD-scid c
/ 
mice with similar reconstitution of human immune compart-
ments (30). Human B cell responses seem to be weak and slow 
in their development in hu-NSG mice. In addition, because 
more restricted expression patterns of EBV latent antigens have 
only been found in germinal center B cells of healthy virus car-
riers (6) and because latency I/II tumors are thought to origi-
nate from EBV-infected centrocytes or centroblasts (31), the 
study of EBV-associated Burkitt and Hodgkin lymphomas and 
T cell responses against these malignancies might be difficult in 
directly target infected cells (9). Based on the results of our in 
vivo experiments, we conclude that CD4+ T cells contribute 
to the control of early EBV infection but are not able to re-
strict viral replication efficiently in the absence of CD8+  
T cells. However, viral titers are further elevated upon addi-
tional depletion of CD8+ T cells in addition to CD4+ T cells, 
suggesting that CD4+ T cells can mediate some immune con-
trol of EBV (11). The inability of CD8+ T cells to control 
EBV infection on their own might reflect the requirement 
for CD4+ T cell help during primary EBV infection (12). 
This analysis demonstrates the usefulness of our in vivo model, 
which allows for the first time to dissect protective mecha-
nisms of human lymphocyte compartments in vivo.
Although  we  demonstrate  protective  primary  immune 
responses against EBV in human immune system–reconstituted 
mice, there are several limitations to this model. The most 
striking is probably the lack of germinal center formation and 
difficulty in developing efficient as well as class-switched 
humoral immune responses. Although we found low concen-
Figure 6.  Development of EBV-associated tumors in EBV-infected hu-NSG mice after T cell depletion. (A) Disseminated tumors in EBV-infected 
animals after T cell depletion. T cell depletion in hu-NSG mice, which had been infected with EBV for 4–5 wk, resulted in splenomegaly and EBV-positive 
tumors either in the kidney, mesenteric lymph node, or liver (arrows). T cell–depleted and EBV-infected hu-NSG mice (EBV/CD4+CD8; n = 11) were 
compared with EBV-infected hu-NSG mice (EBV; n = 13), EBV-infected hu-NSG mice treated with isotype control antibodies (EBV/iso; n = 4), and unin-
fected hu-NSG mice (control; n = 11). Representative images are shown. Data summarize three independent experiments. (B) Immunohistological charac-
terization of representative spleen sections of T cell–depleted and EBV-infected, EBV-infected and mock-treated, or uninfected hu-NSG mice. Splenic 
architecture was assessed by hematoxylin and eosin staining (HE), EBV-infected cells were identified by either EBER in situ hybridization (EBER) or stain-
ing with EBNA2-specific antibodies (EBNA2), and T and B cell content was characterized by CD3- and CD20-specific antibody staining, respectively. Bars: 
(HE) 500 µm; (CD3/EBER and CD20/EBNA2) 100 µm.JEM VOL. 206, June 8, 2009 
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on human bone marrow–derived cells and by H2 molecules 
on mouse stromal cells seems to favor different affinities and 
specificities  than  those  observed  in  humans  with  matching 
MHC type. This shortcoming of dominant EBV epitope rec-
ognition during infection in NSG mice can be overcome by 
introducing HLA transgenes, such as HLA-A2 in our case, into 
this mouse background. Accordingly, we were able to detect 
latent and lytic EBV antigen–specific T cell responses against 
dominant peptide epitopes from EBV-infected hu-NSG-A2 
mice ex vivo. Interestingly and similar to human EBV carriers, 
lytic EBV-specific T cells were detected with nearly 1 log 
higher frequencies than latent EBV antigen specificities (34). 
Therefore, HLA transgenes seem to overcome one of the limi-
tations of human immune responses in hu-NSG mice, and 
allow this immunocompetent small animal model with human 
immune system components to develop protective T cell 
responses against EBV infection with similar specificities to 
human virus carriers.
Because EBV-specific T cells are considered to be the cor-
nerstone of immune control against this oncogenic and persis-
tent -herpesvirus (9, 10), we propose to further characterize 
the innate and adaptive immune responses that lead to this   
T cell–based immune control. We also plan to evaluate vaccine 
our model. Latency II tumors, however, have been observed 
in EBV-infected and human B cell–reconstituted NOD-scid 
mice, suggesting that these hosts allow signaling for germinal 
center formation. Because these mice are unable to reconsti-
tute human T cells after HPC transfer alone (32), immunologi-
cal studies are not possible in this model. Encouragingly, 
however, latency I/II patterns were recently also described in 
EBV-infected BALB/c Rag2/ c
/ mice with reconsti-
tuted human immune system components (33), suggesting that 
the mode of EBV infection and/or of the developing EBV-
specific immune control might allow different latent EBV in-
fections  even  in  mice  with  compromised  germinal  center 
development. Furthermore, the EBV-specific T cell response 
in hu-NSG mice seems to favor subdominant EBV-derived 
peptide epitopes (9), and we were unable to detect T cells of in 
humans dominant specificities ex vivo. A possible explanation 
for this might be the suboptimal selection of human T cells and 
their TCRs on mouse thymic epithelial cells and on human 
bone marrow–derived cells. Even so, others and we have re-
ported that human T cells recognize EBV-infected B cells after 
EBV infection of hu-NSG mice (this study and reference 30), 
and this recognition can be blocked with antibodies against 
human MHC molecules, the selection of EBV-specific T cells 
Figure 7.  Elevated viral loads in T cell–depleted and EBV-infected hu-NSG mice. (A) Splenic EBV loads were determined by quantitative real-time 
PCR 4 wk after EBV infection. Viral titers were calculated from three independent experiments with a total of 39 animals. No EBV titers were detected in 
uninfected hu-NSG mice (control). Samples were analyzed at least in duplicates, and statistical significance was calculated using the Mann-Whitney U 
test. (B) Total splenic EBV loads were determined by multiplying splenic viral loads determined as in A with total splenocyte numbers determined by 
counting. Results are shown for seven control mice, nine EBV-infected mice, four EBV-infected and isotype control antibody–treated mice, and eight  
T cell–depleted and EBV-infected mice. Statistical significance was calculated using the Mann-Whitney U test. (C) EBV episome copy numbers in 106 sple-
nocytes were determined in EBV-infected hu-NSG mice after CD4+ (CD4) and CD8+ (CD8) T cell single depletions, as well as double depletion 
(CD4+CD8). Composite data of two independent experiments are shown and were statistically analyzed using the Mann-Whitney U test. (D) Total viral 
loads per spleen were calculated from the viral copy numbers per 106 cells multiplied by the total counted splenocyte numbers. Statistical significance 
was assessed with the Mann-Whitney U test. Horizontal bars represent means.1432 PROTECTIVE IMMUNE RESPONSES AGAINST EBV IN MICE | Strowig et al.
described (45). In brief, target cells were labeled with PKH26 (Sigma-Aldrich) 
and incubated with T cell clones at the effector/target ratios. Cells were har-
vested after 4 h; TO-PRO-3-iodide (Invitrogen), a membrane-imperme-
able DNA stain, was added to each culture (0.5 µM final concentration); and 
cells analyzed by flow cytometry. Background and maximum TO-PRO-3- 
iodide stainings were obtained by incubation of target cells with medium   
and detergent, respectively. The percent specific lysis was calculated as (% TO-
PRO-3-iodide+PKH26+ cells in effector/target cell co-culture  TO-PRO-
3-iodide+PKH26+ cells in medium)/(% TO-PRO-3-iodide+PKH26+ cells in 
detergent  TO-PRO-3-iodide+PKH26+ cells in medium) × 100%.
Degranulation assay. To characterize the multifunctionality of EBV-spe-
cific T cell clones, we stimulated T cell clones at an effector/target ratio of 5:1 
with autologous LCLs for 6 h in the presence of anti-CD107 antibody. To 
detect spontaneous degranulation and cytokine production, a control without 
LCL was included. After 1 h, 1 µg/ml monensin (Sigma-Aldrich) was added 
to all samples. At the end of the incubation, cells were fixed, permeabilized, 
stained with an anti–IFN- antibody, and analyzed by flow cytometry.
Analysis of homeostatic T cell proliferation and survival using   
5-ethynyl-2-deoxyuridine (EdU) and annexin-V. Reconstituted mice 
were injected once intraperitoneally with 100 µg EdU and sacrificed 24 h 
later. For EdU staining, cells were stained first for cell-surface antigens and 
then analyzed for EdU incorporation using the Click-iT EdU AF488 Cell 
Proliferation Assay Kit (Invitrogen) according to the manufacturer’s instruc-
tion. For annexin-V staining, cells were stained first for cell-surface antigens 
and then stained with annexin-V and 7-AAD using the PE Annexin V 
Apoptosis Detection Kit (BD) according to the manufacturer’s instructions.
Quantification of EBV viral loads by quantitative real-time PCR. 
Splenic EBV viral DNA load was quantified by real-time PCR using a Taq-
Man PCR kit and a sequence detector (model 7900; Applied Biosystems). 
DNA was extracted using the Tissue and Blood DNA kit (QIAGEN) or the 
Wizard SV Genomic DNA purification system (Promega), according to the 
manufacturer’s protocol. A region from the BamHI W fragment of EBV was 
amplified using primers 5-GGACCACTGCCCCTGGTATAA-3 and   
5-TTTGTGTGGACTCCTGGGG-3, and detected with the fluorogenic 
probe FAM-TCCTGCAGCTATTTCTGGTCGCATCA-TAMRA. The 
human bcl-2 gene was amplified using primers 5-CCTGCCCTCCTTC-
CGC-3 and 5-TGCATTTCAGGAAGACCCTGA-3, and detected with 
the fluorogenic probe FAM-CTTTCTCATGGCTGTCC-TAMRA. The 
EBV BamHI W fragment copy number per cell was calculated using the 
formula N = 2 × W/B, where N is the EBV BamHI W copy number/cell, 
W is the EBV BamHI W copy number, and B is the bcl-2 copy number. All 
samples were tested in triplicates.
Immunohistochemistry. Immunohistochemical staining was performed 
on formalin-fixed, paraffin-embedded tissue sections. The antibodies used in 
this study included CD20 (clone L26), CD8 (clone C8/144B), CD45 (clones 
2B11 and PD7/26), CD68 (clone PGM1), EBNA2 (clone PE2), LMP1 
(clone CS1-4; Dako), BZLF1 (clone BZ1; Santa Cruz Biotechnology, Inc.), 
CD3 (clone SP7; Thermo Fisher Scientific), CD21 (clone 2G9), and CD56 
(ERIC-1; Novocastra). In situ hybridization for EBV was performed using 
an EBER probe (Vision Biosystems). Double immunohistochemical staining 
and dual in situ hybridization with immunohistochemical staining was per-
formed using the Bond Max Autostainer (Leica). Formalin-fixed, paraffin-
embedded tissue sections were deparaffinized, and endogenous peroxidase 
was inactivated. For the first antibody, antigen retrieval was performed using 
either the Bond Epitope Retrieval Solution 1 (ER1) or the Bond Epitope 
Retrieval Solution 2 (ER2) at 99–100°C for 20–30 min. After retrieval, the 
sections were incubated sequentially with the primary antibody for 25 min, 
the postprimary antibody for 15 min, and the polymer for 25 min (Bond 
Polymer Detection System; Vision Biosystems), followed by colorimetric 
development with diaminobenzidine (DAB; Vision Biosystems). For the 
subsequent staining with the second antibody, the sections were heated in 
candidates for eliciting these protective T cell responses against 
EBV and other pathogens with exclusive tropism for the human 
hematopoietic lineage. This includes HIV, which has been 
shown to establish infection in mice with reconstituted human 
immune system components (35–42).
MATERIALS AND METHODS
Preparation of humanized mice. NOD/LtSz-scid IL2Rnull (NOD- 
scid c
/) mice were obtained from the Jackson Laboratory and raised un-
der specific pathogen-free conditions. The NOD.Cg-Prkdcscid Il2rgtm1Wjl 
Tg(HLA-A2.1)1Enge/Gck/Roly (NSG-A2) mouse was derived from cross-
ing  NOD.Cg-Prkdcscid  Tg(HLA-A2.1)  Enge/Dvs  mice  (a  gift  from  D. 
Serreze, The Jackson Laboratory, Bar Harbor, ME) with NOD.Cg-Prkdcscid 
Il2rgtm1Wjl/SzJ (NSG) mice at Memorial Sloan-Kettering Cancer Center in 
the laboratory and with the generous support of R. O’Reilly (Memorial 
Sloan-Kettering Cancer Center, New York, NY). Brother and sister mating 
from the F2 offspring was performed with mice identified by PCR to be 
positive for both HLA-A*0201(A2+) and the IL-2R KO. Both hetero-
zygous and homozygous NSG-A2 mice were used in these experiments. 
Human fetal liver was obtained from Advanced Bioscience Resources. The 
tissue was minced and treated with 2 mg/ml collagenase D (Roche) in HBSS 
with CaCl2/MgCl2 for 30 min at room temperature, followed by filtering 
through 70-µm nylon cell strainers (BD). CD34+ human hematopoietic 
stem cells (HSCs) were isolated using the Direct CD34+ Progenitor Cell 
Isolation Kit (Miltenyi Biotec). 2–5-d-old NSG mice were irradiated with 
100 cGy and injected intrahepatically with 1–3 × 105 CD34+ HSCs 6 h after 
irradiation. The mice were bled 10–12 wk after engraftment, and peripheral 
lymphocytes were analyzed by FACS, as described previously (15, 16) to 
check for the reconstitution of the human immune system. Animal protocols 
were approved by the Institutional Animal Care and Use Committee of the 
Rockefeller University.
EBV infection of mice and depletion of T cells. Reconstituted mice 
were infected with EBV at different infectious doses ranging from 105 to 106 
RIU by intraperitoneal injection. In select experiments, human CD4+ and 
CD8+ cells were depleted before EBV infection by intraperitoneal injection 
of 100 µg OKT-4 and 50 µg OKT-8 antibodies (BioLegend) on three con-
secutive days. To deplete T cells for the duration of the experiment, the 
same injection regimen was repeated 2 wk later.
Analysis of EBV-specific T cell responses. 4–10 weeks after infec-
tion, mice were sacrificed and EBV-specific T cell responses were ana-
lyzed using an IFN- ELISPOT assay, as previously described (43). In 
brief, splenocytes were depleted of human CD19+ cells and mouse CD45+  
using anti-CD19 and anti-CD45 microbeads (Miltenyi Biotec). The nega-
tive fraction after the depletion was stimulated with autologous LCLs at a 
ratio of 1:4 for 18 h. Spots were counted with an ELISPOT reader (Auto-
immun Diagnostika GmbH). In blocking experiments, LCL recognition 
by T cells was blocked by preincubation of the target cells with 10 µg/ml 
anti–HLA-A/B/C (clone W6/32; eBioscience), anti–HLA-DR/DP/DQ 
(clone Tü39; BD), and a combination thereof.
Cloning of peptide- and LCL-specific T cells. 10 wk after infection, mice 
were sacrificed and splenocytes were isolated. Cells were then labeled with   
0.5 µM CFSE (Invitrogen) and cultured in complete medium containing a li-
brary of 33 EBV peptides (1 µM each) or autologous irradiated LCLs at a ratio 
of 5:1, respectively. On day 6, CFSElow CD3+ cells were sorted by flow cytom-
etry and cloned by limiting dilution (44). After initial expansion, individual 
clones were screened by IFN- ELISPOT assays after restimulation with the 
library of 33 EBV peptides or autologous irradiated LCLs, respectively. Indi-
vidual clones that recognized the library were further tested against a matrix of 
peptide subpools (Fig. 4 A) to identify the specific cognate peptides.
Cytotoxicity assay. To evaluate the cytotoxic activity of T cell clones   
against the autologous LCLs, cytotoxicity assays were performed as previously JEM VOL. 206, June 8, 2009 
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endogenous alkaline phosphatase using Dual Endogenous Enzyme Block 
(Dako). The sections were then sequentially incubated with the second   
primary antibody, biotinylated link, and streptavidin–alkaline phosphatase 
(LSAB 2 System-AP; Dako) for 25, 15, and 30 min, respectively, followed 
by red chromagen development with permanent red (Dako). With respect 
to dual in situ hybridization–immunohistochemistry, in situ hybridization 
was performed first according to the manufacturer’s instructions (Vision Bio-
systems) with colorimetric development using DAB, followed by immuno-
staining as described for the second antibody. Single immunohistochemical 
staining was performed as described for the first primary antibody.
Production of GFP-expressing EBV. GFP-expressing EBV was pro-
duced as previously described (46). In brief, the EBV lytic cycle was induced 
in EBV-positive AGS cells by addition of PMA and sodium butyrate. EBV 
was further purified by ultracentrifugation over a 25% sucrose step gradient 
and subsequently titered on Raji cells. GFP+ cells were counted 2 d later and 
titers were calculated in RIU.
Tetramer staining. To stain CD8+ T cells, soluble tetrameric complexes of 
HLA-A*0201–peptide were produced using the methods of Busch et al. (47) 
with the following peptides: HIV gag aa 77–85 (SLYNTVATL), EBV LMP2 
aa 426–434 (CLGGLLTMV), and EBV BRLF1 aa 109–117 (YVLDHLIVV). 
For staining with these reagents, hu-NSG splenocytes were incubated for   
30 min at 37°C with 0.5 µg of HLA-A*0201–peptide tetramers (PE-conjugated) 
and washed. The cells were stained with anti-CD8 mAb conjugated with 
FITC (BD) for 30 min at 4°C and washed. The samples were analyzed in a 
flow cytometer.
Statistical  analysis. Statistical analyses were performed with the paired 
two-tailed Student t test or the Mann-Whitney U test, as indicated in the 
figures. The p-value of significant differences is reported. Plotted data repre-
sent means + SD unless otherwise stated.
Online supplemental material. Fig. S1 shows that human immune cells 
reconstitute NOD-scid c
/ mice injected with human fetal liver–derived 
CD34+ HPCs. Fig. S2 demonstrates that transgenic expression of HLA-A2 
does not affect overall reconstitution, homeostatic T cell proliferation, and   
T cell survival. Fig. S3 documents antibody-mediated depletion of human T cells 
in hu-NSG mice. Fig. S4 shows the development of EBV-associated tumors in 
nonlymphoid and secondary lymphoid organs after depletion of human T cells 
in EBV-infected hu-NSG mice. Fig. S5 demonstrates detection of EBV lytic 
replication in human B cells in the spleen of hu-NSG mice. Fig. S6 documents 
that transgenic expression of HLA-A2 does not significantly influence immune 
control of EBV infection in humanized mice. Table S1 lists the EBV-derived 
peptides used in this study. Online supplemental material is available at http://
www.jem.org/cgi/content/full/jem.20081720/DC1.
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